Minimal Residual Disease Testing Market Size

Minimal Residual Disease Testing Market Size

Minimal Residual Disease Testing Market size was valued at around USD 2.45 billion in 2022 and is estimated to reach over USD 4.1 billion by 2032.

To get key market trends

  Download Free Sample

Advancements in minimal residual disease testing technologies result in an improvement in cancer treatment procedures. Additionally, these minimal residual disease tests are specially designed to measure the effectiveness of treatment, help doctors confirm & monitor remissions, and possibly identify an early return of cancer. As per the Leukemia & Lymphoma Society, the most widely used tests to evaluate minimal residual disease are flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) among others.

The minimal residual disease testing market from digital technology is also providing application prospects for personalized minimal residual disease diagnosis through quantifying nucleic acids precisely. These advantages pertaining to minimal residual disease testing are attributable to ongoing R&D activities and significant technological advancements. As a result, the recent technological advancements are set to increase the demand for minimal residual disease testing. Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment.

However, the stringent regulatory framework related to minimal residual disease testing may hamper the market growth. The U.S. FDA has rigid regulatory compliances and complex approval procedures that may obstruct the market gains. The majority of minimal residual tests need a premarket notification, or 510(k) process prior to their commercialization in the market. Such stringent product regulations may lead to penalties and loss of market access in a global marketplace.